Overview

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Status:
Active, not recruiting
Trial end date:
2023-10-04
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to collect and assess long-term safety of nilotinib in patients who are on nilotinib treatment in a Novartis-sponsored, Oncology CD&MA study and are benefiting from the treatment as judged by the investigator.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Lactitol
Criteria
Inclusion Criteria:

- Patient is currently enrolled in a Novartis-sponsored, Oncology CD&MA study receiving
nilotinib and benefiting from the treatment with nilotinib, as determined by the
investigator.

Exclusion Criteria:

- Patient has been permanently discontinued from nilotinib treatment in the parent study
due to unacceptable toxicity, non-compliance to study procedures, withdrawal of
consent or any other reason.

Other protocol-defined inclusion/exclusion criteria may apply.